A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis

Prior treatment

• Evidence of an active and/or concurrent inflammatory skin condition that would interfere with the Investigator or subject-driven evaluations of AD
• Any major surgery within the last 30 days before the first dose of study intervention, or any surgery planned during the course of the study

Other illness

• Any other sound medical, psychiatric, and/or social reason as determined by the investigator
  • Other protocol-defined inclusion/exclusion criteria apply

• Must have diagnosis of atopic dermatitis (AD) at least 12 months prior to screening
• Documented history of inadequate response to treatment with topical medication for at least 4 weeks, unless topical treatments are otherwise medically inadvisable, or has required systemic therapy for control of disease
• All the following must be present to confirm moderate-to-severe AD
  • Eczema Area and Severity Index score ≥ 12 (at Screening and Day 1)
  • Body Surface Area ≥ 10% (at Screening and Day 1)
  • Validated Investigator Global Assessment for Atopic Dermatitis ≥ 3 (at Screening and Day 1)
  • Peak Pruritus Numerical Rating Scale ≥ 4 (at Screening)